Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jan;79(2):333–339. doi: 10.1038/sj.bjc.6690053

Monoclonal antibody ONS-M21 recognizes integrin α3 in gliomas and medulloblastomas

H Kishima 1, K Shimizu 1, K Tamura 1, Y Miyao 1, E Mabuchi 1, E Tominaga 2, J Matsuzaki 2, T Hayakawa 1
PMCID: PMC2362207  PMID: 9888477

Abstract

The monoclonal antibody ONS-M21 recognizes an antigen found on the surface of glioma and medulloblastoma cells but does not react with the antigens of normal brain tissue. We purified and identified the 140-kDa protein by means of an antibody-binding affinity column. This 140-kDa antigen has sequences homologous to the amino-terminal region and five parts of the internal domain of integrin α3. When the integrin α3-related sequences was amplified and used to analyse the mRNA of glioma and medulloblastoma surgical specimens, the transcription level of integrin α3 mRNA appeared to be quantitatively correlated with the grade of malignancy. These findings suggest that the ONS-M21 antibody, which reacts with integrin α3, might be useful in the diagnosis of gliomas and medulloblastomas. © 1999 Cancer Research Campaign

Keywords: glioma, medulloblastoma, monoclonal antibody, integrin α3

Full Text

The Full Text of this article is available as a PDF (500.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boku N., Yoshida S., Ohtsu A., Fujii T., Koba I., Oda Y., Ryu M., Matsumoto T., Hasebe T., Hosokawa K. Expression of integrin alpha 3 in gastric and colorectal cancers: its relation to wall contraction and mode of invasion. Jpn J Cancer Res. 1995 Oct;86(10):934–940. doi: 10.1111/j.1349-7006.1995.tb03004.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Daghighian F., Pentlow K. S., Larson S. M., Graham M. C., DiResta G. R., Yeh S. D., Macapinlac H., Finn R. D., Arbit E., Cheung N. K. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med. 1993 May;20(5):402–409. doi: 10.1007/BF00208998. [DOI] [PubMed] [Google Scholar]
  3. Dan M. D., Earley E. M., Griffin M. C., Maiti P. K., Prashar A. K., Yuan X. Y., Friesen A. D., Kaplan H. A. Human monoclonal antibody BT32/A6 and a cell cycle-independent glioma-associated surface antigen. J Neurosurg. 1995 Mar;82(3):475–480. doi: 10.3171/jns.1995.82.3.0475. [DOI] [PubMed] [Google Scholar]
  4. Dan M. D., Schlachta C. M., Guy J., McKenzie R. G., Dorscheid D. R., Sandor V. A., Villemure J. G., Price G. B. Human antiglioma monoclonal antibodies from patients with astrocytic tumors. J Neurosurg. 1992 Apr;76(4):660–669. doi: 10.3171/jns.1992.76.4.0660. [DOI] [PubMed] [Google Scholar]
  5. Dastidar S. G., Sharma S. K. Monoclonal antibody against human glioblastoma multiforme (U-87MG) immunoprecipitates a protein of molecular mass 38 kDa and inhibits tumor growth in nude mice. J Neuroimmunol. 1995 Jan;56(1):91–98. doi: 10.1016/0165-5728(94)00136-c. [DOI] [PubMed] [Google Scholar]
  6. Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988 Nov 15;62(10):2152–2165. doi: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  7. Elices M. J., Urry L. A., Hemler M. E. Receptor functions for the integrin VLA-3: fibronectin, collagen, and laminin binding are differentially influenced by Arg-Gly-Asp peptide and by divalent cations. J Cell Biol. 1991 Jan;112(1):169–181. doi: 10.1083/jcb.112.1.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Evans A. E., Jenkin R. D., Sposto R., Ortega J. A., Wilson C. B., Wara W., Ertel I. J., Kramer S., Chang C. H., Leikin S. L. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg. 1990 Apr;72(4):572–582. doi: 10.3171/jns.1990.72.4.0572. [DOI] [PubMed] [Google Scholar]
  9. Faillot T., Magdelénat H., Mady E., Stasiecki P., Fohanno D., Gropp P., Poisson M., Delattre J. Y. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery. 1996 Sep;39(3):478–483. doi: 10.1097/00006123-199609000-00009. [DOI] [PubMed] [Google Scholar]
  10. Fradet Y., Cordon-Cardo C., Thomson T., Daly M. E., Whitmore W. F., Jr, Lloyd K. O., Melamed M. R., Old L. J. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1984 Jan;81(1):224–228. doi: 10.1073/pnas.81.1.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Honoré B., Madsen P., Rasmussen H. H., Vandekerckhove J., Celis J. E., Leffers H. Cloning and expression of a cDNA covering the complete coding region of the P32 subunit of human pre-mRNA splicing factor SF2. Gene. 1993 Dec 8;134(2):283–287. doi: 10.1016/0378-1119(93)90108-f. [DOI] [PubMed] [Google Scholar]
  12. Jaskiewicz K., Chasen M. R. Differential expression of transforming growth factor alpha, adhesions molecules and integrins in primary, metastatic liver tumors and in liver cirrhosis. Anticancer Res. 1995 Mar-Apr;15(2):559–562. [PubMed] [Google Scholar]
  13. Moriuchi S., Shimizu K., Miyao Y., Hayakawa T. Characterisation of a new mouse monoclonal antibody (ONS-M21) reactive with both medulloblastomas and gliomas. Br J Cancer. 1993 Nov;68(5):831–837. doi: 10.1038/bjc.1993.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ohtomo T., Tsuchiya M., Sato K., Shimizu K., Moriuchi S., Miyao Y., Akimoto T., Akamatsu K., Hayakawa T., Ohsugi Y. Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions. Mol Immunol. 1995 Apr;32(6):407–416. doi: 10.1016/0161-5890(95)00017-9. [DOI] [PubMed] [Google Scholar]
  15. Okada H., Yoshida J., Seo H., Wakabayashi T., Sugita K., Hagiwara M. Anti-(glioma surface antigen) monoclonal antibody G-22 recognizes overexpressed CD44 in glioma cells. Cancer Immunol Immunother. 1994 Nov;39(5):313–317. doi: 10.1007/BF01519984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Paulus W., Baur I., Schuppan D., Roggendorf W. Characterization of integrin receptors in normal and neoplastic human brain. Am J Pathol. 1993 Jul;143(1):154–163. [PMC free article] [PubMed] [Google Scholar]
  17. Romeijn P., Lenthall R., Stavrou D., Melcher D., Ladyman H., Ritter M. A. Identification of glioma-associated antigen MUC 2-63 as CD44. Br J Cancer. 1994 Nov;70(5):799–803. doi: 10.1038/bjc.1994.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schold S. C., Jr, Zalutsky M. R., Coleman R. E., Glantz M. J., Friedman A. H., Jaszczak R. J., Bigner S. H., Bigner D. D. Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol. 1993 Jun;28(6):488–496. [PubMed] [Google Scholar]
  19. Schrappe M., Bumol T. F., Apelgren L. D., Briggs S. L., Koppel G. A., Markowitz D. D., Mueller B. M., Reisfeld R. A. Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27. Cancer Res. 1992 Jul 15;52(14):3838–3844. [PubMed] [Google Scholar]
  20. Shimizu K., Park K. C., Tamura K., Kishima H., Kawata H., Yoshimura Y., Sekimori Y., Miyao Y., Hayakawa T. Internalization with high targeting potential of mouse monoclonal antibody ONS-M21 recognizing human malignant glioma antigen. Cancer Lett. 1998 May 15;127(1-2):171–176. doi: 10.1016/s0304-3835(98)00030-5. [DOI] [PubMed] [Google Scholar]
  21. Sriramarao P., Steffner P., Gehlsen K. R. Biochemical evidence for a homophilic interaction of the alpha 3 beta 1 integrin. J Biol Chem. 1993 Oct 15;268(29):22036–22041. [PubMed] [Google Scholar]
  22. Suzuki H., Shibata H., Murakami M., Sato A., Naito M., Ichihara A., Matsumoto A., Tsujimoto G., Hirasawa A., Horie K. Modulation of angiotensin II type 1 receptor mRNA expression in human blood cells: comparison of platelets and mononuclear leucocytes. Endocr J. 1995 Feb;42(1):15–22. doi: 10.1507/endocrj.42.15. [DOI] [PubMed] [Google Scholar]
  23. Takada Y., Murphy E., Pil P., Chen C., Ginsberg M. H., Hemler M. E. Molecular cloning and expression of the cDNA for alpha 3 subunit of human alpha 3 beta 1 (VLA-3), an integrin receptor for fibronectin, laminin, and collagen. J Cell Biol. 1991 Oct;115(1):257–266. doi: 10.1083/jcb.115.1.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tamura K., Shimizu K., Yamada M., Okamoto Y., Matsui Y., Park K. C., Mabuchi E., Moriuchi S., Mogami H. Expression of major histocompatibility complex on human medulloblastoma cells with neuronal differentiation. Cancer Res. 1989 Oct 1;49(19):5380–5384. [PubMed] [Google Scholar]
  25. Tsuji T., Hakomori S., Osawa T. Identification of human galactoprotein b3, an oncogenic transformation-induced membrane glycoprotein, as VLA-3 alpha subunit: the primary structure of human integrin alpha 3. J Biochem. 1991 Apr;109(4):659–665. doi: 10.1093/oxfordjournals.jbchem.a123436. [DOI] [PubMed] [Google Scholar]
  26. Weitzman J. B., Chen A., Hemler M. E. Investigation of the role of beta 1 integrins in cell-cell adhesion. J Cell Sci. 1995 Nov;108(Pt 11):3635–3644. doi: 10.1242/jcs.108.11.3635. [DOI] [PubMed] [Google Scholar]
  27. Weitzman J. B., Hemler M. E., Brodt P. Reduction of tumorigenicity by alpha 3 integrin in a rhabdomyosarcoma cell line. Cell Adhes Commun. 1996 Jul;4(1):41–52. doi: 10.3109/15419069609010762. [DOI] [PubMed] [Google Scholar]
  28. Zhao J., Araki N., Nishimoto S. K. Quantitation of matrix Gla protein mRNA by competitive polymerase chain reaction using glyceraldehyde-3-phosphate dehydrogenase as an internal control. Gene. 1995 Apr 3;155(2):159–165. doi: 10.1016/0378-1119(94)00895-y. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES